RE:RE:RE:RE:TODAY's VOLUME GV
I wonder if there is a relationship between the 150,000 private share sale to a USA buyer and the trades on Friday. I doubt it. But it is fun to speculate if someone is building a position.
Probably just ordinary stuff.
Have a look over on Agora at SanFran's post.
I am becoming more convinced that until there is a significant material scientific finding (e.g. success of the BETonMACE trial, complete success of the zen3694 mCRPC trial) there will be no interest from BP. Perhaps if some orphan trial results show great success things will move fast. Likewise the mCRPC trial could really drive things fast but we are not hearing from Zenith.
The early results and post hoc results have resulted in a share price that went from $.20 in late June 2013 to $2.00 plus recently. Paid analysts are putting out valuations from $6.00 to $12.00 (for what that is worth).
Don has said he does not have interest or conttact with from senior BP execs.
So I would really like to hear from posters that have studied many biotech businesses across hundreds of start ups over the past 20 years to provide information on when BP gets interested and what various sceniarious have unfolded...successes and failures.
We know that apabetalone is unique in it's MOA and could be break through science if successful. It could have an enormous impact on science, medicine and exploration of new compounds of which RVX already has 1500 and Zenith has 2500.
Also, both RVX and Zenith seem to be directing their efforts at unmet needs. We know that they have been researching for 16 years and have some very significant patents and some very promising scientific findings at Zenith and RVX.
And yet, all of this adds up to only $2.00/share. It's a high risk, knowledge based bet at this stage. If the BoM futility analysis fails this stock is dead even though there will be tremendous IP value remaining for someone like Dart.
Add to this the financial insecurity and we remain in doubt.
GLTA
Toinv